Business Wire

CA-PSMF

12.1.2021 14:02:34 CET | Business Wire | Press release

Share
Dr. Mike Durkin Assumes Role as Vice Chairman of Patient Safety Movement Foundation Board of Directors

The Patient Safety Movement Foundation (PSMF) , a global non-profit on a mission to achieve zero preventable patient deaths by 2030, has appointed Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc to serve as vice chairman of the board of directors. Dr. Durkin will work alongside Chairman Michael A.E. Ramsay, MD, FRCA to provide guidance and strategic support of the organization’s goal to create safer and more reliable healthcare systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005212/en/

“Dr. Durkin has been an invaluable member of the Patient Safety Movement Foundation board since he joined in 2018, and we are pleased he has accepted this leadership role,” said Dr. Ramsay. “His experience leading the National Patient Safety Improvement Programme for the National Health Service (NHS) England and work with the World Health Organization’s international development of patient safety systems make him an ideal fit to help lead our organization as we continue to grow globally.”

Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. From 2012 to 2017, he served as the national director of patient safety for England’s NHS. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities. He served as executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people, prior to becoming the national director in 2012. His passion for patient safety led him to assemble the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. In 2015, he was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019).

“I am honored to be appointed as vice chairman of the board of directors of the Patient Safety Movement Foundation,” states Durkin. “With the recent launch of our new commitment model and amid a global pandemic, I believe the healthcare industry across the globe is ready and prepared for change and I look forward to working alongside the leadership team to further our shared mission.”

Durkin was appointed officer of the Order of the British Empire (OBE) by Her Majesty The Queen for his services to patient safety and in 2018 was selected as an inaugural member of the International Academy of Safety and Quality. Durkin holds an honorary doctorate from the University of the West of England and he was awarded the highest accolade of the Royal College of Physicians of London for service to patient safety, their Honorary Fellowship in 2017. He is chair of the management board of NICE National Clinical Guideline Centre and sits on multiple national and international research, policy and patient safety advisory boards.

To learn more about the Patient Safety Movement Foundation and its leadership team, visit: https://patientsafetymovement.org/about/

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers and private payers together under the same cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org to learn more, and follow PSMF on Linkedin , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 07:00:00 CET | Press release

Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic solutions at the congress Galderma is committed to raising awareness of the impact of menopause on the skin, fostering meaningful dialogue between patients and healthcare professionals, and advancing science-backed solutions by incorporating menopausal status into all injectable aesthetics clinical trials Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye